Search research articles
Contact Us
Filters
Showing results (1-10 of 113) with videos related to
Page
of 12
Sort By:
Blood
|
February 14, 2015
Separating the wheat from the chaff in cHL
James S Blachly
Blood
|
February 27, 2016
Ribosomal revelation
James S Blachly
Current Hematologic Malignancy Reports
|
February 20, 2016
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents
Joseph Maly, James S Blachly
British Journal of Haematology
|
August 8, 2014
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
James S Blachly, Robert A Baiocchi
Leukemia & Lymphoma
|
March 16, 2013
Emerging drug profile: cyclin-dependent kinase inhibitors
James S Blachly, John C Byrd
Seminars in Oncology
|
April 5, 2016
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia
James S Blachly, John C Byrd, Michael Grever
The New England Journal of Medicine
|
December 29, 2018
Case 28-2018: A Man with Epistaxis, Pain and Erythema of the Forearm, and Pancytopenia
Kerry A Rogers, James S Blachly, Michael R Grever
Haematologica
|
December 1, 2022
The present and future of measurable residual disease testing in acute myeloid leukemia
James S Blachly, Roland B Walter, Christopher S Hourigan
Blood Reviews
|
August 12, 2014
Hairy cell leukemia: Update on molecular profiling and therapeutic advances
Michael R Grever, James S Blachly, Leslie A Andritsos
Scientific Reports
|
February 9, 2020
Quantifying Hematopoietic Stem Cell Clonal Diversity by Selecting Informative Amplicon Barcodes
Emily M Teets, Charles Gregory, Jami Shaffer, et al.
Page
of 12
Search research articles
Search
Showing results (1-10 of 113) with videos related to
Sort By:
Page
of 12
Blood
|
February 14, 2015
Separating the wheat from the chaff in cHL
James S Blachly
Blood
|
February 27, 2016
Ribosomal revelation
James S Blachly
Current Hematologic Malignancy Reports
|
February 20, 2016
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents
Joseph Maly, James S Blachly
British Journal of Haematology
|
August 8, 2014
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
James S Blachly, Robert A Baiocchi
Leukemia & Lymphoma
|
March 16, 2013
Emerging drug profile: cyclin-dependent kinase inhibitors
James S Blachly, John C Byrd
Seminars in Oncology
|
April 5, 2016
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia
James S Blachly, John C Byrd, Michael Grever
The New England Journal of Medicine
|
December 29, 2018
Case 28-2018: A Man with Epistaxis, Pain and Erythema of the Forearm, and Pancytopenia
Kerry A Rogers, James S Blachly, Michael R Grever
Haematologica
|
December 1, 2022
The present and future of measurable residual disease testing in acute myeloid leukemia
James S Blachly, Roland B Walter, Christopher S Hourigan
Blood Reviews
|
August 12, 2014
Hairy cell leukemia: Update on molecular profiling and therapeutic advances
Michael R Grever, James S Blachly, Leslie A Andritsos
Scientific Reports
|
February 9, 2020
Quantifying Hematopoietic Stem Cell Clonal Diversity by Selecting Informative Amplicon Barcodes
Emily M Teets, Charles Gregory, Jami Shaffer, et al.
Page
of 12